Novogen Ltd., of Sydney, named Justine Stehn director of the anti-tropomyosin (ATM) program, and appointed Peter Gunning to its scientific advisory panel for ATM technology. Read More

Nuvilex Inc., of Silver Spring, Md., acquired a 14.5 percent equity interest in SGAustria Pte. Ltd. (Austrianova), which owns Austrianova Singapore Pte. Ltd. The issuance of shares by Austrianova fulfils an obligation to Nuvilex that was part of an asset purchase agreement between both companies pertaining to the acquisition of Bio Blue Bird AG. Read More

SHANGHAI – Neuralstem Inc. has dosed its first patient with NSI-566 stem cells, commencing the Phase I/II trial in China for ischemic stroke. Read More

HONG KONG – A collaborative team from Hong Kong and mainland China has discovered an antiviral peptide that is a promising candidate for treating patients infected with the emergent Middle East respiratory syndrome (MERS) coronavirus, for which there are currently no effective treatments. Read More

HONG KONG – In the wake of an outbreak, two Chinese vaccine makers have filed applications for clinical trials for their vaccines for H7N9 avian flu and are waiting for approvals from the China Food and Drug Administration (CFDA). Read More

HONG KONG – Looking to solidify its pipeline and extend patent protection for some of its top selling oncology products, Takeda Pharmaceutical Co. has launched a series of late-stage trials, including a Phase III clinical trial in Asia for its oral proteasome inhibitor MLN9708 (ixazomib citrate). Much of the work will be done in China. Read More